RxDoctor Payments Data

James John, MD

Internal Medicine · Albemarle, NCNPI 1588628549

Payments from drug & device makers

$9,829in general payments, 2019–2025

Across 584 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$904
  • Novo Nordisk$851
  • AstraZeneca$674
  • Amgen$511
  • Lilly USA, LLC$502
  • Daiichi Sankyo Inc.$481
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$9,829100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)59$904
Novo Nordisk67$851
AstraZeneca(2 entities)35$674
Amgen34$511
Lilly USA, LLC30$502
Daiichi Sankyo Inc.24$481
Pfizer30$464
GSK20$390
Boehringer Ingelheim22$380
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$310
Esperion Therapeutics, Inc.13$245
Antares Pharma, Inc.10$230
Ironwood Pharmaceuticals, Inc12$211
Bayer15$206
Viiv Healthcare Company9$196
Biohaven Pharmaceuticals, Inc.8$186
Astellas Pharma US Inc13$181
Novartis10$175
Shield Therapeutics Inc10$164
Johnson & Johnson11$149
Abbott8$143
Otsuka America Pharmaceutical, Inc.6$135
Xeris Pharmaceuticals, Inc.9$134
Halozyme Inc6$131
Amarin Pharma, Inc.7$117
Merck6$113
Eisai Inc.6$110
Gilead5$109
Lundbeck LLC5$103
Kowa Pharmaceuticals America, Inc.7$97
Sumitomo Pharma America, Inc.6$95
Paratek Pharmaceuticals, Inc.6$90
Sanofi-aventis U.S. LLC5$85
Viatris Specialty LLC4$81
Takeda Pharmaceuticals U.S.A., Inc.5$77
Dynavax Technologies Corporation4$64
Biohaven Pharmaceutical Holding Company Ltd.3$63
Mylan Specialty L.p.3$61
Sunovion Pharmaceuticals Inc.4$61
Dexcom, Inc.3$57
Irhythm Technologies, Inc.1$51
Tactile Systems Technology Inc2$38
Arbor Pharmaceuticals, Inc.2$38
Phathom Pharmaceuticals, Inc.2$37
Organogenesis Inc.1$36
Actelion Pharmaceuticals US, Inc.1$29
Exact Sciences2$29
Nestle Healthcare Nutrition Inc.2$26
Corcept Therapeutics1$25
Aimmune Therapeutics, Inc.1$24
Inspire Medical Systems, Inc.1$21
Hologic Sales And Service, LLC1$20
Boston Scientific1$20
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Heartflow, Inc.1$17
Intra-sana Laboratories1$16
Vertex1$15
Circassia Inc.1$14
Almatica Pharma LLC1$13
Cequr Corporation1$9

How this compares

$9,829 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$131,014
Medicare patients
301
Services billed
6,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide151$229,532
OzempicSemaglutide116$181,893
EliquisApixaban144$148,516
FarxigaDapagliflozin Propanediol140$131,747
JardianceEmpagliflozin95$102,799
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$61,850
TrulicityDulaglutide25$45,107
RybelsusSemaglutide21$38,132
LinzessLinaclotide37$37,105
JanuviaSitagliptin Phosphate21$32,486
Repatha SureclickEvolocumab38$32,274
XareltoRivaroxaban21$15,636
GemtesaVibegron13$15,461
MyrbetriqMirabegron13$13,062
Rosuvastatin Calcium819$11,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$502$274,638176 claims
Novo NordiskOzempic, Rybelsus$851$220,025137 claims
PfizerEliquis, Paxlovid$464$152,581176 claims
AstraZenecaFarxiga, Symbicort$674$141,099169 claims
Boehringer IngelheimJardiance$380$102,79995 claims
GSKTrelegy Ellipta$390$61,85068 claims
AbbVieLinzess, Synthroid$904$39,90871 claims
MerckJanuvia$113$32,48621 claims
Johnson & JohnsonXarelto$149$15,63621 claims
Sumitomo Pharma America, Inc.Gemtesa$95$15,46113 claims
Astellas Pharma US IncMyrbetriq$181$13,06213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Albemarle

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →